Ambry genetics' care program validated for accuracy in identifying high-risk patients for hereditary cancer testing

Aliso viejo, calif.--(business wire)--ambry genetics, now a wholly owned subsidiary of tempus ai, inc. (nasdaq: tem) company and a leader in clinical genomic testing, announced today that a peer-reviewed study validating the accuracy of the ambry care program® (care) for hereditary cancer risk assessment has been published in the journal of the national comprehensive cancer network. the study, “validation of a digital tool that uses national testing guidelines to identify individuals at risk fo.
TEM Ratings Summary
TEM Quant Ranking